Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIGN: Atrasentan in IgA Nephropathy
NCT04573478Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2020
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Atrasentan with Placebo (2 arms). Primary endpoints: Change in proteinuria at 36 weeks, Number of Subjects With Treatment-Emergent Adverse Events at 48 weeks and 3 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
atrasentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04573478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573478.